Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D and methylarginines in chronic kidney disease (CKD)

Study design awaiting verification · PLoS ONE · 2017

Original publication title

Vitamin D and methylarginines in chronic kidney disease (CKD)

Claudia Torino; Patrizia Pizzini; Sebastiano Cutrupi; Rocco Tripepi; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali

© 2017 Torino et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3 to 4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.

Source: Background

Abstract: What methods does the paper describe?

In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.

Source: Methods

Abstract: Results

Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70 to 0.81), 12 week 0.72 μMol/L (95%CI: 0.66 to 0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70 to 0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66 to 0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82 to 1.00), 12 week 0.94 μMol/L (95%CI: 0.82 to 0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82 to 1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88 to 1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.

Source: Results

Abstract: Conclusions

Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3 to 4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.

Source: Conclusions
Authors’ abstract

Background

Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.

Methods

In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.

Results

Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70 to 0.81), 12 week 0.72 μMol/L (95%CI: 0.66 to 0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70 to 0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66 to 0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82 to 1.00), 12 week 0.94 μMol/L (95%CI: 0.82 to 0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82 to 1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88 to 1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.

Conclusions

Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3 to 4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.

Publication and source details

Original title: Vitamin D and methylarginines in chronic kidney disease (CKD)

Claudia Torino; Patrizia Pizzini; Sebastiano Cutrupi; Rocco Tripepi; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali

PLoS ONE · 2017

Competing Interests: CZ received honoraria for lectures from AbbVie, Amgen, Genzyme, Roche, Shire. FM received honoraria for lectures by Amgen and Shire and GT by AbbVie. The other authors report no conflict of interest.This does not alter our adherence to PLOS ONE policies on sharing data and materials.

* E-mail: carmine.zoccali@tin.it
© 2017 Torino et al2017Torino et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100006483AbbVieOur institution received funding by AbbVie for the PENNY study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:26:47.175164+00:00

DOI: 10.1371/journal.pone.0185449 · PMC5627906